drugset / Trial / NCT05682170
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
NaSequentialOpen-labelTreatment
Summary
A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-07-02
- Completion
- 2024-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | Oral |
| Subject | ZN-d5 | Unknown | — | Oral |